Dialysis Concentrate Market - 2024-2031
Description
DIALYSIS CONCENTRATE MARKET SIZE
Dialysis Concentrate Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 5.3% during the forecast period (2024-2031).
Dialysis concentrate is made up of purified water, glucose (https://www.datamintelligence.com/research-report/glucose-market), and electrolytes. It is used in hemodialysis, where the solution is created according to the requirement and aids in electrolyte regulation and the removal of metabolic waste products. The dialysis concentrate used in dialysis is created according to the patient's needs, assisting in electrolyte regulation and maintaining an acid-base balance to promote the removal of metabolic excretes from the body.
MARKET SUMMARY
Metrics Details
Market CAGR 5.3%
Segments Covered By Type, By Application, By Dialysis Site, and By Region
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region Asia Pacific
Largest Market Share North America
For more details on this report, Request for Sample (https://www.datamintelligence.com/download-sample/dialysis-concentrate-market)
MARKET DYNAMICS
The rise in rates of kidney disorders, complications associated with kidney transplants (https://www.datamintelligence.com/research-report/kidney-transplant-market), and the prevalence of lifestyle and chronic diseases are some of the primary drivers driving the dialysis concentrate market.
An increase in the number of patients suffering from hypertension and diabetes will drive the market growth
The global dialysis concentrates market has been developing due to factors such as an increase in the number of patients suffering from hypertension and diabetes and an increase in the number of patients with end-stage renal disease. Furthermore, factors such as product technological advancements, patients' lack of preference for kidney transplantation, increased investment in the development of new products, and government reimbursement for the treatment of kidney diseases and end-stage renal disease are expected to propel the global dialysis concentrate market forward.
According to World Health Organization, hypertension affects an estimated 1.28 billion persons aged 30 to 79 worldwide, with the majority (two-thirds) residing in low- and middle-income nations. An estimated 46% of persons with hypertension are completely ignorant of their illness.Hypertension is recognized and treated in less than half of individuals (42 percent). The International Diabetes Federation Diabetes Atlas, tenth edition 2021, contains the most up-to-date statistics, data, and projections on diabetes worldwide. Diabetes will affect approximately 537 million persons (20-79 years) in 2021. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million.
Furthermore, the proportion of the world's population aged 60 and up will nearly double from 12 percent to 22 percent between 2015 and 2050.By 2023, the number of persons aged 60 and more will outweigh youngsters under five.By 2050, 80% of the world's elderly will live in low- and middle-income countries.The population is aging at a considerably higher rate than in the past.(Source :World Health Organization), this population will more likely to be suffered by chronic kidney diseases thus boosting the growth of dialysis concentrate market.
Complications associated with dialysis treatment is likely to hamper the market growth
Complications associated with dialysis treatment, such as infections, hypotension, fluid overload, and access point bleeding, are expected to hamper the market growth in the coming years.
COVID-19 IMPACT ANALYSIS
COVID-19 has caused widespread disruption in healthcare workflows around the world. As a result of the disease forcing several industries, including numerous sub-domains of health care, to close their doors temporarily, there has been an increase in the mortality rate among dialysis patients during COVID-19. Patients on long-term dialysis were more than five times more likely to be infected with COVID-19 and nearly four times more likely to die than the general population, according to a Canadian study published in the Canadian Medical Association Journal (CMAJ) in February 2021. Furthermore, there is a considerable risk of infectious illness transmission during dialysis, which has hampered the expansion of the dialysis concentrate industry. The survey was done in 19 large hospitals in India (8 public and 11 private) to see how lockdown affected the care of renal disease patients, including those on dialysis, after the first three weeks of lockdown. As a result, the number of dialysis patients at these centers declined from 2,517 to 2,404 between 2019 and 2020, according to this survey. Around 710 patients (28%) skipped one or more dialysis sessions, 69 (3%) required emergency dialysis, 104 (4%) ceased reporting, and 9 (0.36%) died out of a total of 2,517 patients.
MARKET SEGMENT ANALYSIS
The hemodialysis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Based on application, it is bifurcated into hemodialysis and peritoneal dialysis. The hemodialysis segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to increase in geriatric population and incidences of renal diseases, especially end stage renal disease (ESRD) globally as well as rise in incidences of diabetes and hypertension and shortage of kidneys for transplantation, which increase the use of hemodialysis and hemodialysis concentrate.
According to the United States Renal Data System 2020 Annual Data Report , In the United States, nearly 786,000 people have ESKD, also known as an end-stage renal disease (ESRD), with 71% receiving dialysis and 29% receiving a kidney transplant. For every two women who develop ESKD, three men develop ESKD. For every white person who gets ESKD, three black people get it.
MARKET GEOGRAPHICAL SHARE
North America region holds the largest market share of the global dialysis concentrate market
North America is anticipated to dominate the dialysis concentrate market, globally. The factors attributed to because of an increase in cases of End Stage Renal Disease, Chronic Kidney Diseases, diabetes, and hypertension, as well as a surge in diagnosis rates Furthermore, an increase in the number of hemodialysis and peritoneal dialysis procedures is a major factor driving market growth. In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, in July 2019, Baxter has begun a clinical trial in the United States for an on-demand peritoneal dialysis solution system. Furthermore, advancements in various dialysis concentrate from established key players, in the United States, are likely to drive the market growth in North America.
MARKET COMPETITIVE LANDSCAPE
The dialysis concentrate market is highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Asahi Kasei Medical Co Ltd (https://www.asahi-kasei.co.jp/medical/en/dialysis/), B.Braun Melsungen AG, Baxter International Inc, Farmasol, Fresenius Medical Care, Hemoclean, Medites Pharma, NiproRenal Solutions, Surni Group, Weigao Group, Taishikang among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the dialysis concentrate market globally. For instance, In June 2021, Rockwell Medical announces the extension of a multi-year distribution agreement for dialysis concentrates with Nipro Medical Corporation.
FARMASOL
Overview:
Farmasol (https://farmasol.com.tr/products/hemodialysis-concentrates/diasol-acidic-bicarbonate-hemodialysis-solutions-with-acetate/), a global medical technology company specializing in hemodialysis consumables, is a leader in developing, manufacturing, and supplying an innovative range of products compatible with all global dialysis machines, as well as services for dialysis patients. Since 2005, Farmasol has continuously evolved to advance high-quality hemodialysis products while also shaping high-quality and cost-effective solutions to help people live healthier lives. Farmasol's product portfolio includes more than 20 marketable products, including new technology dialyzers, hemodialysis solutions with over 150 formulas, various disinfectants for all machines, bicarbonate cartridges and bag cartridges, bloodlines, and fistula needles.
Product Portfolio:
Basic Bicarbonate Hemodialysis Solutions: There are two dilution rates for DIASOL B 35 Basic Bicarbonate Hemodialysis Solutions and FARMACART Cartridge Bicarbonate.
Hemodialysis Solutions based on Basic Bicarbonate (B 35) (1/34)
B 35 Hemodialysis Solutions with Basic Bicarbonate (1/44)
Dialysis Concentrate Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 5.3% during the forecast period (2024-2031).
Dialysis concentrate is made up of purified water, glucose (https://www.datamintelligence.com/research-report/glucose-market), and electrolytes. It is used in hemodialysis, where the solution is created according to the requirement and aids in electrolyte regulation and the removal of metabolic waste products. The dialysis concentrate used in dialysis is created according to the patient's needs, assisting in electrolyte regulation and maintaining an acid-base balance to promote the removal of metabolic excretes from the body.
MARKET SUMMARY
Metrics Details
Market CAGR 5.3%
Segments Covered By Type, By Application, By Dialysis Site, and By Region
Report Insights Covered Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region Asia Pacific
Largest Market Share North America
For more details on this report, Request for Sample (https://www.datamintelligence.com/download-sample/dialysis-concentrate-market)
MARKET DYNAMICS
The rise in rates of kidney disorders, complications associated with kidney transplants (https://www.datamintelligence.com/research-report/kidney-transplant-market), and the prevalence of lifestyle and chronic diseases are some of the primary drivers driving the dialysis concentrate market.
An increase in the number of patients suffering from hypertension and diabetes will drive the market growth
The global dialysis concentrates market has been developing due to factors such as an increase in the number of patients suffering from hypertension and diabetes and an increase in the number of patients with end-stage renal disease. Furthermore, factors such as product technological advancements, patients' lack of preference for kidney transplantation, increased investment in the development of new products, and government reimbursement for the treatment of kidney diseases and end-stage renal disease are expected to propel the global dialysis concentrate market forward.
According to World Health Organization, hypertension affects an estimated 1.28 billion persons aged 30 to 79 worldwide, with the majority (two-thirds) residing in low- and middle-income nations. An estimated 46% of persons with hypertension are completely ignorant of their illness.Hypertension is recognized and treated in less than half of individuals (42 percent). The International Diabetes Federation Diabetes Atlas, tenth edition 2021, contains the most up-to-date statistics, data, and projections on diabetes worldwide. Diabetes will affect approximately 537 million persons (20-79 years) in 2021. By 2030, the overall number of diabetics is expected to reach 643 million, and by 2045, it will reach 783 million.
Furthermore, the proportion of the world's population aged 60 and up will nearly double from 12 percent to 22 percent between 2015 and 2050.By 2023, the number of persons aged 60 and more will outweigh youngsters under five.By 2050, 80% of the world's elderly will live in low- and middle-income countries.The population is aging at a considerably higher rate than in the past.(Source :World Health Organization), this population will more likely to be suffered by chronic kidney diseases thus boosting the growth of dialysis concentrate market.
Complications associated with dialysis treatment is likely to hamper the market growth
Complications associated with dialysis treatment, such as infections, hypotension, fluid overload, and access point bleeding, are expected to hamper the market growth in the coming years.
COVID-19 IMPACT ANALYSIS
COVID-19 has caused widespread disruption in healthcare workflows around the world. As a result of the disease forcing several industries, including numerous sub-domains of health care, to close their doors temporarily, there has been an increase in the mortality rate among dialysis patients during COVID-19. Patients on long-term dialysis were more than five times more likely to be infected with COVID-19 and nearly four times more likely to die than the general population, according to a Canadian study published in the Canadian Medical Association Journal (CMAJ) in February 2021. Furthermore, there is a considerable risk of infectious illness transmission during dialysis, which has hampered the expansion of the dialysis concentrate industry. The survey was done in 19 large hospitals in India (8 public and 11 private) to see how lockdown affected the care of renal disease patients, including those on dialysis, after the first three weeks of lockdown. As a result, the number of dialysis patients at these centers declined from 2,517 to 2,404 between 2019 and 2020, according to this survey. Around 710 patients (28%) skipped one or more dialysis sessions, 69 (3%) required emergency dialysis, 104 (4%) ceased reporting, and 9 (0.36%) died out of a total of 2,517 patients.
MARKET SEGMENT ANALYSIS
The hemodialysis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
Based on application, it is bifurcated into hemodialysis and peritoneal dialysis. The hemodialysis segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to increase in geriatric population and incidences of renal diseases, especially end stage renal disease (ESRD) globally as well as rise in incidences of diabetes and hypertension and shortage of kidneys for transplantation, which increase the use of hemodialysis and hemodialysis concentrate.
According to the United States Renal Data System 2020 Annual Data Report , In the United States, nearly 786,000 people have ESKD, also known as an end-stage renal disease (ESRD), with 71% receiving dialysis and 29% receiving a kidney transplant. For every two women who develop ESKD, three men develop ESKD. For every white person who gets ESKD, three black people get it.
MARKET GEOGRAPHICAL SHARE
North America region holds the largest market share of the global dialysis concentrate market
North America is anticipated to dominate the dialysis concentrate market, globally. The factors attributed to because of an increase in cases of End Stage Renal Disease, Chronic Kidney Diseases, diabetes, and hypertension, as well as a surge in diagnosis rates Furthermore, an increase in the number of hemodialysis and peritoneal dialysis procedures is a major factor driving market growth. In addition, organic and inorganic strategies such as mergers and acquisitions and partnerships within key market players will strengthen their product portfolio in the studied market which will drive the market. Also, several product launches in the market will lead to lucrative growth of the market. For instance, in July 2019, Baxter has begun a clinical trial in the United States for an on-demand peritoneal dialysis solution system. Furthermore, advancements in various dialysis concentrate from established key players, in the United States, are likely to drive the market growth in North America.
MARKET COMPETITIVE LANDSCAPE
The dialysis concentrate market is highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Asahi Kasei Medical Co Ltd (https://www.asahi-kasei.co.jp/medical/en/dialysis/), B.Braun Melsungen AG, Baxter International Inc, Farmasol, Fresenius Medical Care, Hemoclean, Medites Pharma, NiproRenal Solutions, Surni Group, Weigao Group, Taishikang among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the dialysis concentrate market globally. For instance, In June 2021, Rockwell Medical announces the extension of a multi-year distribution agreement for dialysis concentrates with Nipro Medical Corporation.
FARMASOL
Overview:
Farmasol (https://farmasol.com.tr/products/hemodialysis-concentrates/diasol-acidic-bicarbonate-hemodialysis-solutions-with-acetate/), a global medical technology company specializing in hemodialysis consumables, is a leader in developing, manufacturing, and supplying an innovative range of products compatible with all global dialysis machines, as well as services for dialysis patients. Since 2005, Farmasol has continuously evolved to advance high-quality hemodialysis products while also shaping high-quality and cost-effective solutions to help people live healthier lives. Farmasol's product portfolio includes more than 20 marketable products, including new technology dialyzers, hemodialysis solutions with over 150 formulas, various disinfectants for all machines, bicarbonate cartridges and bag cartridges, bloodlines, and fistula needles.
Product Portfolio:
Basic Bicarbonate Hemodialysis Solutions: There are two dilution rates for DIASOL B 35 Basic Bicarbonate Hemodialysis Solutions and FARMACART Cartridge Bicarbonate.
Hemodialysis Solutions based on Basic Bicarbonate (B 35) (1/34)
B 35 Hemodialysis Solutions with Basic Bicarbonate (1/44)
Table of Contents
180 Pages
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Market Definition and Overview
- 3. Executive Summary
- 3.1. Market Snippet By Type
- 3.2. Market snippet By Application
- 3.3. Market Snippet By End User
- 3.4. Market Snippet by Region
- 4. Market Dynamics
- 4.1. Market Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Technological Advancements
- 4.1.1.2. Rising Prevalence of kidney Related Diseases
- 4.1.2. Restraints:
- 4.1.2.1. Complication associated with dialysis treatment.
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Regulatory Analysis
- 6. COVID-19 Analysis
- 6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
- 7.1.2. Market Attractiveness Index, By Type Segment
- 7.2. Acid Concentrates*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 7.3. Bicarbonate Concentrates
- 7.4. Peritoneal Dialysis
- 8. By Application
- 8.1. Introduction
- 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Hemodialysis*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 8.3. Peritoneal Dialysis
- 9. By Dialysis Site
- 9.1. Introduction
- 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 9.1.2. Market Attractiveness Index, By Dialysis Site Segment
- 9.2. Hospital*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
- 9.3. Clinics & Dialysis Centers
- 9.4. Home Dialysis
- 9.5. Others
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. The U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. U.K.
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Dialysis Site
- 11. Competitive Landscape
- 11.1. Key Developments and Strategies
- 11.2. Company Share Analysis
- 11.3. Product Benchmarking
- 12. Company Profiles
- 12.1. Farmasol*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
- 12.2. Asahi Kasei Medical Co Ltd
- 12.3. B.Braun Melsungen AG
- 12.4. Baxter International Inc
- 12.5. Fresenius Medical Care
- 12.6. Hemoclean
- 12.7. Medites Pharma
- 12.8. NiproRenal Solution
- 12.9. Surni Group
- 12.10. Weigao Group
- 12.11. Taishikang
- 12.12. Advin Healthcare(*LIST NOT EXHAUSTIVE)
- 13. DataM Intelligence
- 13.1. Appendix
- 13.2. About Us and Services
- 13.3. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
